Skip to main content
. 2021 Jun 29:M21-1269. doi: 10.7326/M21-1269

Appendix Figure 1. Priority populations for ACTIV.

Appendix Figure 1. Priority populations for ACTIV. To appropriately prioritize agents for the master protocols, the desired target populations needed to be agreed on by the ACTIV Therapeutics-Clinical Working Group. After much deliberation, the group decided given the high hospitalization and death rate early in the pandemic that the COVID-19 patient population would be prioritized in the following order for agent review: 1) hospitalized/moderately ill (non-ICU) and critically ill/ventilated (ICU), 2) outpatient/ambulatory ill, and 3) prophylaxis. ACTIV = Accelerating COVID-19 Therapeutic Interventions and Vaccines; ICU = intensive care unit.

To appropriately prioritize agents for the master protocols, the desired target populations needed to be agreed on by the ACTIV Therapeutics-Clinical Working Group. After much deliberation, the group decided given the high hospitalization and death rate early in the pandemic that the COVID-19 patient population would be prioritized in the following order for agent review: 1) hospitalized/moderately ill (non-ICU) and critically ill/ventilated (ICU), 2) outpatient/ambulatory ill, and 3) prophylaxis. ACTIV = Accelerating COVID-19 Therapeutic Interventions and Vaccines; ICU = intensive care unit.